GSK's anti-cancer drug pipeline is increasing with the addition of one other antibody conjugate, or ADC. It’s the second time in as many months that GSK has turned to Hansoh Pharma for one among its China-based biotech medication. Beneath deal phrases introduced Wednesday, GSK pays $185 million upfront for rights to HS-20093, a Hansoh ADC examined for lung most cancers. […]